August 14, 2024 01:31 AM EDTUpdated 06:37 AM
Diagnostics

To get back to growth, Il­lu­mi­na CEO says it's sim­pli­fy­ing DNA se­quenc­ing and analy­sis

Jared Whitlock

Features Editor

On Tues­day, Il­lu­mi­na laid out a three-year plan for in­vestors de­tail­ing how the strug­gling DNA se­quenc­ing com­pa­ny plans to get back to growth. To do …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times